SHARE
COPY LINK

HEALTH

French pharma giant Sanofi to begin trials on second Covid vaccine

French pharmaceutical firm Sanofi on Friday announced the launch of human trials of its second Covid-19 vaccine, with its first still in the testing phase after having fallen behind in development.

French pharma giant Sanofi to begin trials on second Covid vaccine
Photo: Joel Saget/AFP

Sanofi and US company Translate Bio are developing the vaccine based on messenger RNA technology.

The phase 1 and 2 trials aim to verify that the vaccine is not dangerous and to provide initial information on its effectiveness.

Phase 3 would be carried out on many more patients to determine its effectiveness.

The first trials will include 415 people, with inital results expected in the third quarter.

Messenger RNA technology is also used in the Pfizer/BioNTech and Moderna vaccines, already authorised in the European Union, the United States and elsewhere.

It is the second vaccine developed by Sanofi against the coronavirus.

An earlier candidate, developed with Britain’s GSK, is recombinant protein-based, but its development is several months behind schedule and testing is only in phase 2, with hopes to launch it in late 2021.

Sanofi has also agreed to help produce Covid vaccines developed by Pfizer and Johnson & Johnson.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

HEALTH

Carte vitale: France to adopt a new ‘biometric’ health card

The French parliament has approved a €20 million project to launch a 'biometric' version of the carte vitale health insurance card.

Carte vitale: France to adopt a new 'biometric' health card

As part of the French government’s package of financial aid for the cost-of-living crisis, €20 million will be set set aside to launch a biometric health card, after an amendment proposed by senators was approved.

Right-wing senators made this measure a “condition” of their support for the financial aid package, according to French left-wing daily Libération, and on Thursday the measure was approved by the Assemblée nationale.

While it sounds quite high tech, the idea is relatively simple, according to centre-right MP Thibault Bazin: the carte vitale would be equipped with a chip that “contains physical characteristics of the insured, such as their fingerprints” which would allow healthcare providers to identify them.

The carte vitale is the card that allows anyone registered in the French health system to be reimbursed for medical costs such as doctor’s appointments, medical procedures and prescriptions. The card is linked to the patient’s bank account so that costs are reimbursed directly into the bank account, usually within a couple of days.

READ ALSO How a carte vitale works and how to get one

According to the centre-right Les Républicains group, the reason for having a ‘biometric’ carte vitale is to fight against welfare fraud.

They say this would have two functions; firstly the biometric data would ensure the card could only be used by the holder, and secondly the chip would allow for instant deactivation if the card was lost of stolen.

Support for the biometric carte vitale has mostly been concentrated with right-wing representatives, however, opponants say that the implementation of the tool would be costly and lengthy.

It would involve replacing at least 65 million cards across France and repurposing them with biometric chips, in addition to taking fingerprints for all people concerned.

Additionally, all healthcare professionals would have to join the new system and be equipped with devices capable of reading fingerprints. 

Left-leaning representatives have also voiced concerns regarding the protection of personal data and whether plans would comply with European regulations for protecting personal data, as the creation of ‘biometric’ carte vitales would inevitably lead to the creation of a centralised biometric database. Additionally, there are concerns regarding whether this sensitive personal information could be exposed to cybercrime, as the health insurance system in France has been targeted by hackers in the past.

Finally, there is concern that the amount of financial loss represented by carte vitale fraud has been overestimated. The true figures are difficult to establish, but fraud related to carte vitale use is only a small part of general welfare fraud, which also covers unemployment benefits and other government subsidy schemes.

The scheme is set to begin in the autumn, but there us no information on how this will be done, and whether the biometric chip will just be added to new cards, or whether existing cards will be replaced with new ones. 

SHOW COMMENTS